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Objectives: This study evaluated intracardiac angiotensin-converting
enzyme inhibition as an adjuvant to cardioplegia and examined its
effects on hemodynamic, metabolic, and ultrastructural postisch-
emic outcomes.
Methods: The experiments were performed with an isolated,
erythrocyte-perfused, rabbit working-heart model. The hearts ex-
cised from 29 adult New Zealand White rabbits (2950  200 g)
were randomly assigned to four groups. Two groups received
quinaprilat (1 g/mL), initiated either with cardioplegia (n  7) or
during reperfusion (n  7). The third group received L-arginine (2
mmol/L) initiated with cardioplegia (n  7). Eight hearts served as
a control group. Forty minutes of preischemic perfusion were followed
by 60 minutes of hypothermic arrest and 40 minutes of reperfusion.
Results: All treatments substantially improved postischemic recovery of external
heart work (62%  6%, 69%  3%, and 64%  5% in quinaprilat during
cardioplegia, quinaprilat during reperfusion, and L-arginine groups, respectively, vs
35%  5% in control group, P  .001) with similarly increased external stroke
work and cardiac output. When administered during ischemia, quinaprilat signifi-
cantly improved recovery of coronary flow (70%  8%, P  .028 vs quinaprilat
during reperfusion [49%  5%] and P  .023 vs control [48%  6%]). L-Arginine
(55%  7%) showed no significant effect. Postischemic myocardial oxygen con-
sumption remained low in treatment groups (4.6  1.2 mL  min1  100 g1, 6.0 
2.2 mL  min1  100 g1, and 4.7  1.6 mL  min1  100 g1 in quinaprilat during
cardioplegia, quinaprilat during reperfusion, and L-arginine groups, respectively, vs
4.2  0.8 mL  min1  100 g1 in control group), even though cardiac work was
markedly increased. High-energy phosphates, which were consistently elevated in
all treatment groups, showed a significant increase in adenosine triphosphate with
quinaprilat during ischemia (2.24  0.14 mol/g vs 1.81  0.12 mol/g in control
group, P  .040). Ultrastructural grading of mitochondrial damage revealed best
preservation with quinaprilat during ischemia (100% [no damage], P .001 vs control).
Conclusion: These experimental findings have clinical relevance regarding preven-
tion of postoperative myocardial stunning and low coronary reflow in patients
undergoing heart surgery.
In recent years angiotensin-converting enzyme (ACE) inhibitors have beenshown to exert a protective effect in various settings of acute ischemia andreperfusion.1-3 Most evidence suggests that increased synthesis of nitric oxide,mediated through accumulated bradykinin, plays a pivotal role in protectionagainst ischemia-reperfusion injury.3-5 The tissue activities of these paracrinemediators thus are increased by inhibition of intracardiac ACE and kininase II,
accounting for the reproducibility of cardioprotective effects at the organ level.
Acute postischemic administration of ACE inhibitors has shown some clinical
benefits for cardiac protection in such settings as thrombolysis6 or the acute phase
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of myocardial infarction.7-9 The application of these drugs
during induced cardiac arrest would allow even earlier
initiation of ACE inhibition, concurrent with the ischemic
event. Cardioplegic solutions thus constitute an ideal vehi-
cle for the introduction of agents aiming to improve myo-
cardial and vascular protection during ischemia and reper-
fusion. ACE inhibitors might be an attractive adjuvant in
this setting. As opposed to standard cardioplegic solutions,
their cardioprotective mechanisms involve modification of
endogenous mediators to support the heart’s own defense
against ischemia. Furthermore these mediators may help to
preserve endothelial function. However, the reduced meta-
bolic activity during hypothermia may limit such an endo-
genous protection, and data about the efficacy of ACE inhibi-
tion during cold blood cardioplegia are still sparse.10-12 The
rationale for clinical application remains unsettled.
This study evaluated the acute inhibition of intracardiac
ACE by means of quinaprilat as adjuvant to cold blood
cardioplegia. Hemodynamic, metabolic, and ultrastructural
postischemic outcomes in the isolated erythrocyte-perfused
working heart were analyzed. Quinaprilat initiated during
cardioplegia was compared with administration during
reperfusion only to investigate the influence of timing. L-
Arginine initiated during cardioplegia provided comparison
with an alternative treatment option of clinical significance
and served as a positive control with respect to the putative
role of nitric oxide as mediator during ACE inhibition.
Methods
Experimental Design
The study was performed as a randomized experimental trial with
an isolated, erythrocyte-perfused, rabbit working-heart model
(Hugo Sachs Elektronik, Freiburg, Germany) that has been de-
scribed in detail in previous publications by Podesser and col-
leagues.13,14 The perfusate consisted of a Krebs-Henseleit buffer–
based suspension of purified bovine erythrocytes (hematocrit 30%)
oxygenated with low gas (75% nitrogen/20% oxygen/5% carbon
dioxide) to provide a constant PO2 of 100  10 mm Hg. Compo-
sition of the buffer was as follows: 118-mmol/L sodium chloride,
4.7-mmol/L potassium chloride, 2.5-mmol/L calcium chloride,
1.2-mmol/L magnesium sulfate, 1.2-mmol/L potassium dihydro-
gen phosphate, 0.5-mmol/L sodium ethylenediaminetetraacetate,
25-mmol/L sodium hydrogen carbonate, 11.1-mmol/L glucose,
2.5-IU/L insulin, and 0.2-g/dL bovine albumin.
The hearts excised from 29 adult New Zealand White rabbits,
weighing 2950  200 g, were randomly assigned to four groups.
Two groups received 0.3 mg quinaprilat (1 g/mL), initiated either
during ischemia with the first cardioplegic reinfusion (ischemia
quinaprilat group, n  7) or during reperfusion with the hot shot
(reperfusion quinaprilat group, n  7). The third group received
120 mg L-arginine (2 mmol/L) initiated with the first cardioplegic
reinfusion, in parallel with the ischemia quinaprilat group (arginine
group, n  7), and 8 hearts served as a control group. For the
purpose of randomization the assignment of animals was subject to
chance, and all experiments were conducted in a randomly chosen
order. A preischemic aortic flow of less than 250 mL/min served
as an exclusion criterion.
The perfusion was conducted according to a standardized pro-
tocol, which is depicted in Figure 1. The Langendorff mode
provided constant pressure coronary perfusion at 70 mm Hg. In the
subsequent preischemic working-heart mode, after left atrial load-
ing (mean atrial pressure of 5 mm Hg), the left ventricle ejected the
perfusate against a predefined afterload, giving rise to 70 mm Hg
mean aortic pressure. Decreasing cardiac output was accompanied
by slight elevation of atrial pressure and decline in aortic pressure,
thus mimicking clinical conditions. Hearts were beating spontane-
ously at a mean rate of 3 Hz throughout the perfusion. The
cardioplegia was performed as multidose cold blood cardioplegia
according to Buckberg (Buckberg Kardioplegie; Ko¨hler Chemie
GmbH, Koblenz, Germany) at a 4:1 ratio of perfusate to Buckberg
solution, administered at 8°C with a constant pressure of 50 mm
Hg. During ischemia, after the heart had been arrested with the first
cardioplegic infusion (induction), drugs were added to the pool of
perfusate, which then provided the blood fraction for subsequent
cardioplegic reinfusions. This guaranteed precise dosage of drugs
in small volumes (cardioplegia) and provided adequate concentra-
tions at the time of reperfusion. Quinaprilat for the ischemia
quinaprilat group and L-arginine for the arginine group were added
Figure 1. Experimental protocol. Drugs were admixed with blood fractions of respective cardioplegic infusions and
with perfusates of subsequent reperfusion. LD, Preischemic Langendorff mode; WH, preischemic working-heart
mode; rLD, Langendorff mode during reperfusion; rWH, working-heart mode during reperfusion; Ind, induction of
cardioplegia; Re, reinfusion; IQ, ischemia quinaprilat group; ARG, arginine group; PQ, reperfusion quinaprilat
group.
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before the first reinfusion. Quinaprilat for the reperfusion quinapri-
lat group was added before the hot shot that initiated the reperfu-
sion (Figure 1).
Drugs
Quinaprilat (Go¨ 9018-1; Go¨decke AG, Freiburg, Germany) is a
parenterally applicable carboxyl-type ACE inhibitor. Even though
its initial elimination half-life in plasma is short (2 hours),
quinaprilat has a prolonged terminal half-life of 25 hours, which
corresponds to its pharmacologic activity.15,16 This phenomenon is
explained by its high-affinity binding to tissue ACE with consec-
utive slow dissociation.15 L-Arginine (Merck 1.01542; Merck AG,
Darmstadt, Germany) constitutes the physiologic substrate for all
types of nitric oxide synthases. Its pharmacologic effects are
thought to be mediated exclusively by its ability to increase the
synthesis of nitric oxide.
Hemodynamic Data Acquisition
The myocardial function was assessed by cardiac output (identical
to the left atrial flow in a closed system), the external heart work
(cardiac output times mean aortic pressure, indicating the pressure-
volume work performed per minute), and the external stroke work
(cardiac output times mean aortic pressure divided by heart rate,
the most accurate indicator of myocardial function in this model).
The external heart work was expressed in grams per meter per
minute (the value in milliliters per minute per millimeter of mer-
cury multiplied by 0.0136) and referenced to the heart weight. The
coronary flow was calculated by subtracting aortic flow from left
atrial flow. The hemodynamic baseline was defined as the mean
obtained from readings at 10, 15, and 25 minutes during the
preischemic working-heart mode, when stable conditions were
achieved. To adjust for minor deviations in baseline hemodynam-
ics, readings from the reperfusion period were expressed as recov-
ery (percentage of baseline). The mean recovery encompassed all
time points of the working-heart period during reperfusion.
Biochemical Evaluation
An arterial and coronary venous blood gas analysis performed in
each working-heart period (after 10 minutes in preischemic working-
heart mode and working-heart mode during reperfusion) allowed
the calculation of the myocardial oxygen consumption according
to the Fick law (oxygen consumption  arterial-venous oxygen
saturation difference  hemoglobin concentration  1.34 mL 
g1  coronary flow  heart weight1). For estimation of nitric
oxide synthesis, nitrite and nitrate levels were measured at baseline
(after 10 minutes in preischemic working-heart mode) and during
reperfusion (5, 15, and 25 minutes during working-heart mode
during reperfusion). Two milliliters of perfusate drawn from the
venous effluent was centrifuged, and the supernatant was stored at
80°C. Then protein precipitation with acetonitrile was performed
with the postcolumn derivatization technique, as described by
Green and associates.17 A cadmium/copper column was inserted
into the high-performance liquid chromatographic system after the
gel permeation column for reduction of nitrate to nitrite. For
analysis of high-energy phosphates, freeze-clamped biopsy sam-
ples were taken from the apical myocardium at the end of the
reperfusion and stored in liquid nitrogen. Concentrations of ade-
nine nucleotides (adenosine triphosphate [ATP], adenosine diphos-
phate, and adenosine monophosphate) and creatine phosphate (CP)
were determined by high-performance liquid chromatography ac-
cording to the method of Fu¨rst and Hallstro¨m18 and expressed in
micromoles per gram wet weight.
Ultrastructural Evaluation
Two myocardial specimens were harvested from the septal and
external portions of the left ventricular wall and fixed with 4%
paraformaldehyde and 1% glutaraldehyde in 0.1-mol/L cacodylate
buffer. Histologic processing was performed according to standard
methods. Transmission electron microscopy (JEM-1200 EX;
JEOL Ltd, Akishima, Japan) at a magnification of 45,000 (3
microscopic fields for each heart) was used to determine mito-
chondrial damage. This evaluation was conducted independently
by two histologists who were blinded to sample origins. Mitochon-
drial damage was graded according to the following semiquanti-
tative scheme19: grade 0, no visible damage, normal matrix gran-
ules; grade 1, loss of matrix granules and light clearing of matrix;
grade 2, moderate clearing of matrix, moderate swelling, and
partial fragmentation of cristae; grade 3, severe clearing, severe
swelling, and loss of cristae; and grade 3a, amorphous dense
granules. Each individual heart was assigned an overall grade for
mitochondrial damage, which was derived as the mean of the three
microscopic fields.
Animal Care
This study was approved by the ethical committee of the Univer-
sity of Vienna and by the Ministry of Science, Republic of Austria.
Care of animals was in accordance with the “Guide for the Care
and Use of Laboratory Animals” prepared by the Institute of
Laboratory Animal Resources, National Research Council, and
published by the National Academy Press, revised 1996.
Statistical Analysis
All parametric data were referenced to the heart weight (as mea-
sured before perfusion) and expressed as mean  SEM. Analysis
of variance (ANOVA) and analysis of covariance were performed
with the SPSS 8.0 software package (SPSS Inc, Chicago, Ill).
Statistical significant results were specified post hoc with the
Fisher least significant difference test. Ordinal parameters (ultra-
structural grading) were transformed for ANOVA by the Fechner
marginal normalization.
Results
Hemodynamic Data
Baseline hemodynamics demonstrated comparable preisch-
emic conditions without significant differences (external
heart work in ischemia quinaprilat group 29.3  2.4 [g  m
 min1]  g1, reperfusion quinaprilat group 29.0  2.5 [g
 m  min1]  g1, arginine group 31.2 2.9 [g  m  min1]
 g1, and control group 30.0  1.8 [g  m  min1]  g1;
coronary flows in ischemia quinaprilat group 2.7  0.5 mL
 min1  g1, reperfusion quinaprilat group 3.2  0.5 mL
 min1  g1, arginine group 2.5  0.4 mL  min1  g1,
and control group 2.8  0.3 mL  min1  g1, P  .2). The
spontaneous heart rate showed only minor variability
among groups. During reperfusion, all hearts promptly re-
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sumed sinus rhythm with adequate heart rate (ischemia
quinaprilat group 196 17 beats/min, reperfusion quinapri-
lat group 197  9 beats/min, arginine group 205  5
beats/min, and control group 186  8 beats/min).
The postischemic myocardial function was markedly im-
proved in all treatment groups, with substantially elevated
cardiac output (mean recoveries in ischemia quinaprilat
group 68%  5%, P  .001 vs control group, reperfusion
quinaprilat group 76%  3%, P  .001 vs control group,
and arginine group 66%  5%, P  .001 vs control group)
relative to the control group (43% 5%). These differences
were paralleled in the external heart work (mean recoveries
in ischemia quinaprilat group 62%  6%, P  .001 vs
control group, reperfusion quinaprilat group 69%  3%,
P  .001 vs control group, arginine group 64%  5%, P 
.001 vs control group, and control group 35% 5%; Figure
2, A). The recovery of external stroke work (mean recoveries in
ischemia quinaprilat group 67%  4%, P  .001 vs control
group, reperfusion quinaprilat group 71%  3%, P  .001 vs
control group, arginine group 67% 4%, P .001 vs control
group, and control group 44%  5%) confirmed the marked
improvement in myocardial function and stroke volume, be-
cause differences in heart rate were only minor.
Coronary flow during reperfusion was diminished in all
Figure 2. Postischemic recovery of hemodynamic parameters. Time points define time in minutes elapsed in
Langendorff (rLD) and working-heart (rWH) modes respectively during reperfusion; Recovery denotes percentage
referenced to preischemic baseline. Bar heights represent mean; error bars represent SEM. Diagonally filled bars,
Ischemia quinaprilat group; white bars, reperfusion quinaprilat group; dotted bars, arginine group; black bars,
control group. A. External heart work. Asterisk indicates P < .01; dagger indicates P < .001; double dagger
indicates P  .012. B. Coronary flow. Asterisk indicates P  .018 vs control group and P  .029 vs reperfusion
quinaprilat group; dagger indicates P  .023 vs control group and P  .028 vs reperfusion quinaprilat group.
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groups (mean recoveries in ischemia quinaprilat group 68%
 9%, reperfusion quinaprilat group 51%  5%, arginine
group 55%  7%, and control group 49%  7%); however,
recovery was significantly different among groups (overall
P  .011 by ANOVA with multiple adjustments of Tukey-
Kramer). When quinaprilat was administered during isch-
emia, the recovery of coronary flow was substantially im-
proved relative to both postischemic administration and
control values. These differences were most significant at 3
and 5 minutes after initiation of the postischemic working-
heart period (eg, at 5 minutes, P  .023 vs control group
and P .028 vs reperfusion quinaprilat group; Figure 2, B).
Treatment with L-arginine did not yield significant improve-
ment. Analysis of the postischemic time course revealed a
rising trend toward the end of the experiment in the reper-
fusion quinaprilat group relative to other groups.
Biochemical Data
There were no significant differences in preischemic myo-
cardial oxygen consumption. During reperfusion, mean ox-
ygen consumption decreased in all groups (Table 1). Con-
sidering the correlation of oxygen consumption with the
actual cardiac work (r  0.437), the postischemic levels in
treatment groups, especially the ischemia quinaprilat and
arginine groups, appeared relatively low. Because of wide
variations of individual readings, an analysis of covariance
including the external heart work as covariable did not show
any differences to be significant (P  .2). Measurement of
nitrate and nitrite in the perfusion fluid at baseline (ischemia
quinaprilat group 16.6  1.1 mol  L1, reperfusion
quinaprilat group 15.5  4.2 mol  L1, arginine group
12.6  2.6 mol  L1, and control group 19.8  3.3 mol
 L1) as well as after reperfusion (ischemia quinaprilat
group 18.6  1.3 mol  L1, reperfusion quinaprilat group
15.6  4.3 mol  L1, arginine group 13.5  1.7 mol 
L1, and control group 22.8  4.0 mol  L1) showed no
significant differences in accumulation of these metabolites.
Mean levels of ATP and CP were consistently elevated
in all treatment groups relative to control levels. Significant
differences in the ischemia quinaprilat group were seen in
both ATP concentrations (ischemia quinaprilat group
2.24  0.14 mol  g1, P  .040 vs control group,
reperfusion quinaprilat group 2.12  0.21 mol  g1,
arginine group 1.83  0.15 mol  g1, and control group
1.81  0.12 mol  g1) and CP concentrations (ischemia
quinaprilat group 3.34  0.31 mol  g1, P  .056 vs
control group, reperfusion quinaprilat group 2.71  0.48
mol  g1, arginine group, 2.73  0.28 mol  g1, and
control group, 2.50  0.27 mol  g1).
Ultrastructural Data
Treatment groups showed preservation of mitochondrial
integrity superior to that of the control group (P  .006 by
ANOVA; Table 2). Most significant results were observed
in the ischemia quinaprilat group (no visible damage in all
hearts, P  .001 vs control group). Likewise the minor
grade mitochondrial damages observed in the reperfusion
quinaprilat and arginine groups constituted notable im-
provement over the control group (P  .053 and P  .048,
respectively). Representative photomicrographs of mito-
chondrial damages are depicted in Figure 3. Overall, the
assessment by two independent observers yielded a concor-
dance rate of 95%; discordant findings (n  5/105) were
quoted according to the higher grade.
Discussion
Experimental study always raises a question about the va-
lidity of clinical conclusions extrapolated from the results.
In organ preparations, the artificial isolation from interven-
ing systemic influences constitutes the primary limiting
factor. The lack of platelets, leukocytes, and inflammatory
cytokines has to be taken into account. However, cardiople-
gic arrest as a paradigm for global ischemia-reperfusion
injury with comparable separation of the heart from sys-
temic variables lends itself to studies on the isolated heart.
This model offers major advantages, in particular by dem-
onstrating pharmacologic effects at the organ level. Use of
the working-heart perfusion mode and an erythrocyte-
containing perfusate provides a closer approach to in vivo
conditions. The addition of red blood cells to the more
commonly used crystalloid perfusion fluid not only affords
TABLE 1. Myocardial oxygen consumption
Group
Baseline
(mL  min1  g1)
Reperfusion
(mL  min1  g1)
Recovery
(%)
Ischemia
quinaprilat group
7.6 0.9 4.6 1.2 68% 19%
Reperfusion
quinaprilat group
6.8 2.3 6.4 2.9 91% 26%
Arginine group 7.6 1.0 4.7 1.6 56% 14%
Control group 7.2 1.7 4.2 0.8 65% 12%
Data are expressed as mean  SEM. Baseline and reperfusion readings
were obtained at 10 minutes of the preischemic working-heart mode and
10 minutes of the postischemic working-heart mode, respectively.
TABLE 2. Ultrastructural results
Ischemia
quinaprilat
group
Reperfusion
quinaprilat
group
Arginine
group
Control
group
Total microscopic
fields assessed
15 15 18 21
Grade 0 100% 47% 55% 24%
Grade 1 0% 47% 39% 28%
Grade 2 0% 6% 6% 48%
P value vs control
group
.001 .053 .048 –
Percentile distribution of grades of postischemic mitochondrial damage,
with grades as defined in text.
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oxygen-carrying capacity and coronary flow autoregulation
within the physiologic range,20 it also provides crucial bio-
chemical functions, such as buffering of oxygen radicals
and catabolism of nitric oxide.
In our experiment, inhibition of intracardiac ACE and
kininase II during either ischemia or reperfusion was fol-
lowed by markedly improved recovery of myocardial func-
tion relative to control hearts. Treatment with L-arginine
was associated with similar improvement. Quinaprilat and
L-arginine do not convey direct positive inotropic effects, so
the superior myocardial function seems to result from
heightened prevention of myocardial ischemia-reperfusion
damage. Two groups have obtained comparable results with
isolated rat heart preparations, although both perfused the
hearts with Krebs-Henseleit buffer in Langendorff mode
and subjected them to warm cardioplegic arrest. Menasche
and associates10 tested the effects of advance treatment (48
hours) with either captopril or enalapril. Gurevitch and
colleagues11 administered captopril during either cardiople-
gia or reperfusion. Both observed improvements in coro-
nary flow and myocardial recovery. However, the limita-
tions of crystalloid perfusion fluid and the Langendorff
mode have to be taken into account when extrapolating
these results to in vivo conditions.13,20 Lazar and cowork-
ers,12 in a porcine model with regional ischemia followed by
acute surgical revascularization, showed beneficial effects
of systemic enalaprilat administered before cardioplegic
arrest. A reduction in infarct size, less myocardial irritabil-
ity, and superior wall motion were noted.
The beneficial effects of L-arginine on myocardial recov-
ery after cardioplegic arrest were confirmed in several stud-
ies. By adding L-arginine to blood cardioplegic solution,
Mizuno and colleagues21 reversed endothelial dysfunction
and improved myocyte recovery after reperfusion in a por-
cine model. Amrani and coworkers22 concluded that admin-
istration during reperfusion provided improved recovery
after moderate (20°C) and deep (4°C) hypothermia, whereas
only moderate hypothermia was amenable to coadministra-
tion during cardioplegia. A recent phase I pilot study tested
the effects of L-arginine administered during the first 30
Figure 3. Mitochondrial ultrastructure. Representative photomicrographs (original magnification  45,000) depict-
ing range of observed postischemic damages; grading as defined in text. A, No discernable damage (grade 0). B,
Light clearing of matrix with loss of granules (grade 1). C, Additional swelling and partial fragmentation of cristae
(grade 2).
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minutes of cardioplegia on patients undergoing coronary
artery bypass grafting. Although the safety was established,
the release of troponin I was not shown to be reduced after
administration of L-arginine.23
A direct biochemical characterization of the underlying
mediators was not obtained with our working-heart appara-
tus. Our analysis showed that baseline concentrations of
nitrate and nitrite in the perfusate were too high to assess
small differences in nitric oxide production of the coronary
endothelium through nitrate and nitrite determination in the
perfusate. This situation is similar to in vivo conditions.
Only dramatic increases in nitric oxide production (eg, in
septic shock) are reflected by higher concentrations of ni-
trate and nitrite in the plasma.24 However, secondary medi-
ators of ACE inhibition have been well established in the
literature. Linz and colleagues3 elucidated the mediation by
bradykinin and nitric oxide by using their respective inhib-
itors. Likewise, Kitakaze and coworkers4 demonstrated an
equal blunting of ACE inhibitor-induced effects with either
HOE 140 or N-nitro-L-arginine methyl ester. When testing
ramiprilat in isolated guinea pig hearts, Massoudy and co-
workers5 attributed the improved outcome to nitric oxide–
mediated effects. In particular, various cyclic guanosine
monophosphate–independent effects of nitric oxide seem to
be crucial for the cardioprotection. The avid annihilation of
oxygen radicals suggests significant scavenger activity dur-
ing ischemia-reperfusion.5,25,26 Recently, alteration of en-
zyme activities by binding of nitric oxide to heme prosthetic
groups and iron-sulfur centers has received increasing at-
tention. The comparable myocardial recoveries seen with
quinaprilat and L-arginine in our study were consistent with
these findings from the literature. Because no additional
benefits of ACE inhibitors over L-arginine in terms of myo-
cardial protection were seen, the induction of nitric oxide
synthesis alone may be as effective as ACE inhibition.
The myocardial metabolism has to be discussed with
respect to the underlying differences in postischemic myo-
cardial work. In light of the markedly increased postisch-
emic cardiac work, the trend toward relatively lower oxygen
consumption that we observed, especially in the ischemia
quinaprilat and arginine groups, was in keeping with recent
evidence of reduction in oxygen consumption by means of
ACE inhibitors. Zhang and coworkers27 described this ef-
fect after the application of ACE inhibitors to myocardial
tissue preparations and proved that it is mediated by the
bradykinin–nitric oxide axis. However, the high variability
of oxygen consumption in our isolated heart model pre-
cludes further conclusions.
Analysis of high-energy phosphates at the end of our
experimental protocol provided postischemic steady-state
levels, as determined by both synthesis and expenditure.
Both superior preservation of mitochondrial oxidative phos-
phorylation and prevention of the inadequate expenditure of
high-energy compounds precipitated by ischemia-reperfu-
sion damage may account for these results. Additionally, a
direct drug effect, such as the assumed inhibition of en-
zymes in the respiratory chain by nitric oxide,27 might also
be involved. Comparable studies in the literature confirm
favorable preservation of high-energy phosphates, espe-
cially with early initiation of ACE inhibition. Cargnoni and
coworkers1 demonstrated higher recoveries of ATP and CP
after global ischemia and reperfusion in isolated rabbit
hearts treated in advance with quinaprilat. Zhu and col-
leagues28 found that superior myocardial recovery after
bradykinin administration was partially related to conserva-
tion of ATP and CP, which were only elevated when drug
administration was initiated before ischemia.
The functional outcome indicated by high-energy phos-
phate levels is paralleled by markedly improved preserva-
tion of mitochondrial integrity. These data are of particular
interest as they relate to the reduction of oxidative stress
attributed to ACE inhibitors and nitric oxide. Because the
ultrastructural alterations primarily represent membrane dis-
ruption caused by lipid peroxidation, they reflect the ulti-
mate damaging potential of oxygen radicals. Thus their
reduction provides indirect evidence of an antioxidant treat-
ment effect. Various biochemical assays described in the
literature confirm such a reduction in oxidative stress. De-
creases in glutathione release and a lower fraction of its
oxidized form have been associated with the improvement
in myocardial recovery observed after ACE inhibition.1,5
The ability of nitric oxide donors to reduce oxidative stress
was confirmed by means of chemiluminescence.5 Quinapri-
lat, a carboxyl-type ACE inhibitor, lacks the intrinsic anti-
oxidant property often ascribed to sulfhydryl-containing
compounds (eg, captopril).10 Thus our results must be at-
tributable to alterations of the mediator profile, most likely
the increase of nitric oxide or reduction of angiotensin II.
The recovery of coronary flow was significantly im-
proved when quinaprilat was administered during ischemia,
whereas quinaprilat given during reperfusion and L-arginine
both showed no substantial effect. These findings, in accor-
dance with the literature, may be explained by improved
vascular autoregulation by means of preserved endothelial
function or a direct vasodilatory effect.
The lack of significant vasodilation with postischemic
administration argues against a direct vasodilatory drug
effect and suggests a protective effect on vasomotor func-
tion when ACE inhibition is initiated during ischemia. This
hypothesis was supported in two experiments with porcine
models, one in which ACE inhibitors were administered
during short-term ischemia29 and another in which L-argi-
nine was added to blood cardioplegia.21 Both demonstrated
postischemic reductions of endothelium-dependent vasodi-
lation, which were reversed by the respective treatment
modalities. Recent evidence that angiotensin II contributes
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to oxidative vascular injury by inducing generation of su-
peroxide anions in smooth muscle cells through reduced
nicotinamide adenine dinucleotide oxidase activation30,31
may account for additional protection with ACE inhibition
relative to L-arginine. Improved vascular protection is of
particular interest, because standard potassium cardioplegia
is designed primarily for myocardial preservation,32 and the
relatively unprotected vascular structures, especially endo-
thelial cells, appear to be highly susceptible to ischemic
damage.21,33,34 It has been observed that endothelial injury
is an early event during cardioplegic arrest, and functional
disturbance (diminished release of nitric oxide) has been
seen immediately at the beginning of reperfusion21; this
emphasizes the significance of early drug administration to
prevent endothelial stunning. Furthermore, vasomotor dys-
function has been described as an untoward effect of depo-
larizing cardioplegic solutions.21,33,35 Aside from dysfunc-
tional intrinsic regulation of vascular tone, the postischemic
coronary flow may also be compromised by insufficient
coronary reserve or extrinsic compressive forces related to
edema. These forces are in part determined by the state of
the endothelium. However, some aspects related to the
experimental model need to be heeded in this context.
Increased edema and diminished coronary reserve are com-
monly seen in crystalloid-perfused hearts; in our model, this
was avoided by using an erythrocyte-based perfusate.13 The
lack of inflammatory mediators, however, needs to be taken
into account.
Alternatively, one might reason that ACE inhibition has
a direct vasodilatory effect with a latency period. The need
for early ACE inhibition could be explained by ongoing
angiotensin II–mediated vasoconstriction after initiation of
ACE inhibition, related to a prolonged elimination half-life
of angiotensin II in interstitial tissue.36 In support of this
hypothesis is the poorer response in coronary flow seen in
the reperfusion quinaprilat and arginine groups, as well as
the rising trend toward the end of the reperfusion period
seen in the ischemia quinaprilat group. The superior vaso-
dilation observed with early ACE inhibition might be due to
the delayed reduction of angiotensin II constrictor activity,
whereas myocardial protection could be mediated primarily
by the rapidly adjusting bradykinin–nitric oxide system.
Experiments with selective inhibitors of the angiotensin II
type 1 receptor (CV11974, losartan) showed inconclusive
results concerning the effect of angiotensin II on coronary
flow,4,37 and a biochemical confirmation of this hypothesis
is necessary.
Individual pharmacodynamic properties of different
types of ACE inhibitor must also be considered. A recent
study that compared the abilities of ACE inhibitors to en-
hance endothelium-dependent vasodilation in the radial ar-
tery revealed an increased responsiveness with quinaprilat
relative to enalaprilat, which showed no effect relative to
control.37 This difference, explained by the higher affinity
of quinaprilat for tissue ACE,38 might also account for the
improved coronary flow preservation in our study, which
was not seen in the previously mentioned experiment by
Lazar and colleagues.12
In conclusion, quinaprilat administration during cold
blood cardioplegia provides a promising approach for im-
proving both myocardial protection and postischemic coro-
nary flow. In this isolated rabbit heart model, postischemic
hemodynamics, myocardial energy status, and ultrastruc-
tural morphologic characteristics were consistently im-
proved when treatment was initiated during ischemia.
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